IDO cDNA ORF Clone, Human, N-HA tag General Information
Identical with the Gene Bank Ref. ID sequence.
Full length Clone DNA of Human indoleamine 2,3-dioxygenase 1 with N terminal HA tag.
Enhanced CMV promoter
KpnI + XbaI(6kb+1.25kb)
HA Tag Sequence: TATCCTTACGACGTGCCTGACTACGCC
T7( 5' TAATACGACTCACTATAGGG 3' )
BGH( 5' TAGAAGGCACAGTCGAGG 3' )
The plasmid is confirmed by full-length sequencing.
Antibiotic in E.coli
Antibiotic in Mammalian cell
Stable or Transient mammalian expression
Storage & Shipping
Each tube contains lyophilized plasmid.
The lyophilized plasmid can be stored at ambient temperature for three months.
**Sino Biological guarantees 100% sequence accuracy of all synthetic DNA constructs we deliver, but we do not guarantee protein expression in your experimental system. Protein expression is influenced by many factors that may vary between experiments or laboratories.**
IDO cDNA ORF Clone, Human, N-HA tag Validated Images
IDO cDNA ORF Clone, Human, N-HA tag Alternative Names
IDO cDNA ORF Clone, Human;IDO-1 cDNA ORF Clone, Human;INDO cDNA ORF Clone, Human;Indoleamine 2,3‑dioxygenase cDNA ORF Clone, Human
IDO Background Information
Indoleamine 2,3-dioxygenase-1, also known as Indoleamine-pyrrole 2,3-dioxygenase, IDO1 and IDO, is a member of the indoleamine 2,3-dioxygenase family. IDO1 / IDO and tryptophan 2,3-dioxygenase (TDO) are tryptophan-degrading enzymes that catalyze the first step in tryptophan catabolism via the kynurenine pathway. TDO is widely distributed in both eukaryotes and bacteria. In contrast, IDO has been found only in mammals and yeast. In 2007, a third enzyme, indoleamine 2,3-dioxygenase-2 (IDO2), was discovered. IDO2 is found not only in mammals but also in lower vertebrates. IDO1 / IDO is an immunosuppressive molecule inducible in various cells. IDO1 / IDO catalyzes the cleavage of the pyrrol ring of tryptophan and incorporates both atoms of a molecule of oxygen. It mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 / IDO inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. The IDO pathway is activated in multiple tumor types. Selective inhibition of IDO1 may represent an attractive cancer therapeutic strategy via up-regulation of cellular immunity. IDO1 / IDO is an enzyme that suppresses adaptive T-cell immunity by catabolizing tryptophan from the cellular microenvironment. Inhibition of IDO pathway might enhance the efficacy of immunotherapeutic strategies for cancer.
Immune Checkpoint Detection: ELISA Antibodies
Co-inhibitory Immune Checkpoint Targets
Immunotherapy Cancer Immunotherapy Targeted Therapy
indoleamine 2,3-dioxygenase 1
Barnes NA. et al., 2009, J Immunol. 183 (9): 5768-77. Yuasa HJ. et al., 2009, Comp Biochem Physiol B Biochem Mol Biol. 153 (2): 137-44. L b S. et al., 2009, Cancer Immunol Immunother. 58 (1): 153-7. Liu,X. et al., 2010, Blood.115 (17): 3520-30. Sun,T. et al., 2010, Mol Cell Biochem. 342 (1-2): 29-34. Kiank C. et al., 2010, PLoS One. 5 (7): e11825.